Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: A randomized, phase III trial

Katherine A Skorupski, J. M. Uhl, A. Szivek, S. D. Allstadt Frazier, Robert B Rebhun, C. O. Rodriguez

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal chemotherapy protocol. The purpose of this study was to determine whether either of two protocols would be associated with longer disease-free interval (DFI) in dogs with appendicular osteosarcoma following amputation. Dogs with histologically confirmed appendicular osteosarcoma that were free of gross metastases and underwent amputation were eligible for enrollment. Dogs were randomized to receive either six doses of carboplatin or three doses each of carboplatin and doxorubicin on an alternating schedule. Fifty dogs were included. Dogs receiving carboplatin alone had a significantly longer DFI (425 versus 135 days) than dogs receiving alternating carboplatin and doxorubicin (P = 0.04). Toxicity was similar between groups. These results suggest that six doses of carboplatin may be associated superior DFI when compared to six total doses of carboplatin and doxorubicin.

Original languageEnglish (US)
Pages (from-to)81-87
Number of pages7
JournalVeterinary and Comparative Oncology
Volume14
Issue number1
DOIs
StatePublished - Mar 1 2016

Fingerprint

doxorubicin
osteosarcoma
Carboplatin
Osteosarcoma
Doxorubicin
adjuvants
Canidae
Dogs
dogs
amputation
Amputation
dosage
Therapeutics
drug therapy
Adjuvant Chemotherapy
Appointments and Schedules
metastasis
Neoplasm Metastasis
Drug Therapy
toxicity

Keywords

  • Amputation
  • Bone tumour
  • Canine
  • Chemotherapy
  • Clinical trial

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma : A randomized, phase III trial. / Skorupski, Katherine A; Uhl, J. M.; Szivek, A.; Allstadt Frazier, S. D.; Rebhun, Robert B; Rodriguez, C. O.

In: Veterinary and Comparative Oncology, Vol. 14, No. 1, 01.03.2016, p. 81-87.

Research output: Contribution to journalArticle

@article{49c8fc0efe5047aca88e853259790e10,
title = "Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: A randomized, phase III trial",
abstract = "Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal chemotherapy protocol. The purpose of this study was to determine whether either of two protocols would be associated with longer disease-free interval (DFI) in dogs with appendicular osteosarcoma following amputation. Dogs with histologically confirmed appendicular osteosarcoma that were free of gross metastases and underwent amputation were eligible for enrollment. Dogs were randomized to receive either six doses of carboplatin or three doses each of carboplatin and doxorubicin on an alternating schedule. Fifty dogs were included. Dogs receiving carboplatin alone had a significantly longer DFI (425 versus 135 days) than dogs receiving alternating carboplatin and doxorubicin (P = 0.04). Toxicity was similar between groups. These results suggest that six doses of carboplatin may be associated superior DFI when compared to six total doses of carboplatin and doxorubicin.",
keywords = "Amputation, Bone tumour, Canine, Chemotherapy, Clinical trial",
author = "Skorupski, {Katherine A} and Uhl, {J. M.} and A. Szivek and {Allstadt Frazier}, {S. D.} and Rebhun, {Robert B} and Rodriguez, {C. O.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1111/vco.12069",
language = "English (US)",
volume = "14",
pages = "81--87",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma

T2 - A randomized, phase III trial

AU - Skorupski, Katherine A

AU - Uhl, J. M.

AU - Szivek, A.

AU - Allstadt Frazier, S. D.

AU - Rebhun, Robert B

AU - Rodriguez, C. O.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal chemotherapy protocol. The purpose of this study was to determine whether either of two protocols would be associated with longer disease-free interval (DFI) in dogs with appendicular osteosarcoma following amputation. Dogs with histologically confirmed appendicular osteosarcoma that were free of gross metastases and underwent amputation were eligible for enrollment. Dogs were randomized to receive either six doses of carboplatin or three doses each of carboplatin and doxorubicin on an alternating schedule. Fifty dogs were included. Dogs receiving carboplatin alone had a significantly longer DFI (425 versus 135 days) than dogs receiving alternating carboplatin and doxorubicin (P = 0.04). Toxicity was similar between groups. These results suggest that six doses of carboplatin may be associated superior DFI when compared to six total doses of carboplatin and doxorubicin.

AB - Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal chemotherapy protocol. The purpose of this study was to determine whether either of two protocols would be associated with longer disease-free interval (DFI) in dogs with appendicular osteosarcoma following amputation. Dogs with histologically confirmed appendicular osteosarcoma that were free of gross metastases and underwent amputation were eligible for enrollment. Dogs were randomized to receive either six doses of carboplatin or three doses each of carboplatin and doxorubicin on an alternating schedule. Fifty dogs were included. Dogs receiving carboplatin alone had a significantly longer DFI (425 versus 135 days) than dogs receiving alternating carboplatin and doxorubicin (P = 0.04). Toxicity was similar between groups. These results suggest that six doses of carboplatin may be associated superior DFI when compared to six total doses of carboplatin and doxorubicin.

KW - Amputation

KW - Bone tumour

KW - Canine

KW - Chemotherapy

KW - Clinical trial

UR - http://www.scopus.com/inward/record.url?scp=84956596640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956596640&partnerID=8YFLogxK

U2 - 10.1111/vco.12069

DO - 10.1111/vco.12069

M3 - Article

C2 - 24118677

AN - SCOPUS:84956596640

VL - 14

SP - 81

EP - 87

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 1

ER -